Oblenio Bio Raises $62M to Advance Immune Reset Therapy for Autoimmune Diseases
- Category
- · Funding · Global
- Date
- June 30, 2026
- Source
- Femtech Insider
Summary
Cambridge-based Oblenio Bio has closed an oversubscribed $62 million Series B led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor Aditum Bio. The funding will advance LBL-051, a tri-specific T-cell engager designed to achieve a broad immune system reset for patients with refractory autoimmune diseases, into first-in-human clinical trials this year. Autoimmune diseases disproportionately affect women, who… The post Oblenio Bio Raises $62M to Advance Immune Reset Therapy for Autoimmune Diseases first appeared on .
The company works in Therapeutics and Care Delivery, and this round at Series B ($62M) is new money into that part of the market. Compare it with other recent rounds to see whether prices here are rising or holding steady.
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- Femtech Insider Primary source
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.